• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Controversies in the early detection of prostate cancer.

作者信息

Montie J E

机构信息

Department of Urology, Wayne State University School of Medicine, Detroit, Michigan.

出版信息

In Vivo. 1994 May-Jun;8(3):407-11.

PMID:7528555
Abstract

Fundamental issues about early detection of prostate cancer are unresolved. There is controversy over the need for early detection of prostate cancer, based on a relatively small number of lifeyears lost to prostate cancer when compared with other types of cancers. Earlier detection of prostate cancer is possible with PSA-driven strategies based on evidence that there is an interval of probably several years when the PSA is abnormal but the prostate cancer is still in the curative state. Earlier detection may only be advisable in men with risk for premature death from prostate cancer, i.e., younger men. Immediate problems in early detection of prostate cancer include, 1) An apparent indiscriminate use of PSA in all age groups; 2) Probable over treatment in some older patients; and 3) Morbidity from currently available therapies. Physician education about the use of PSA can be accomplished now. More precise characterization of the morbidity of treatment is needed; efforts to improve the quality of surgery, radiation therapy, or alternative treatments are warranted. A marvelous opportunity and challenge are presented in a disease that will become an increasingly important health care issue in our society.

摘要

相似文献

1
Controversies in the early detection of prostate cancer.
In Vivo. 1994 May-Jun;8(3):407-11.
2
[Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma].
Schweiz Med Wochenschr. 1996 Nov 2;126(44):1881-90.
3
Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.前列腺癌。非根治性治疗后的死亡率和发病率以及诊断与治疗方面
Scand J Urol Nephrol Suppl. 1994;167:1-41.
4
Prostate-specific antigen kinetics in localized and advanced prostate cancer.局限性和晚期前列腺癌中前列腺特异性抗原的动力学
BJU Int. 2009 Mar;103(5):578-87. doi: 10.1111/j.1464-410X.2009.08345.x. Epub 2009 Feb 6.
5
[Adenocarcinoma of the prostate].前列腺腺癌
Cas Lek Cesk. 1998 Aug 31;137(17):515-21.
6
Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.亮丙瑞林治疗高危局限性前列腺癌的全球最新进展:美国视角——识别诊断时术后或放疗后有前列腺癌死亡高风险的男性。
BJU Int. 2007 Jan;99 Suppl 1:13-6; discussion 17-8. doi: 10.1111/j.1464-410X.2007.06594.x.
7
Screening for prostate cancer: updated experience from the Tyrol study.前列腺癌筛查:蒂罗尔研究的最新经验
Can J Urol. 2005 Feb;12 Suppl 1:7-13; discussion 92-3.
8
Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.前列腺特异性抗原(PSA)及PSA速率在50岁以下男性前列腺癌检测中的应用
BJU Int. 2007 Apr;99(4):753-7. doi: 10.1111/j.1464-410X.2006.06682.x. Epub 2007 Jan 19.
9
[Advancements in PSA-based screening for prostate cancer].[基于前列腺特异性抗原(PSA)的前列腺癌筛查进展]
Rinsho Byori. 2004 Jul;52(7):611-7.
10
Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.前列腺活检的指征与时机、早期前列腺癌的诊断及其确定性治疗:PSA时代的临床难题
Surg Oncol. 2009 Sep;18(3):192-9. doi: 10.1016/j.suronc.2009.02.006. Epub 2009 Mar 12.